Kevan M. Shokat, PhD: Drugging the Elusive KRAS
Dr. Shokat shifted the paradigm of targeted cancer therapy by drugging an “undruggable” protein and paving the way for future advances.
Archives: Pioneers
Dr. Shokat shifted the paradigm of targeted cancer therapy by drugging an “undruggable” protein and paving the way for future advances.
Dr. Patricia LoRusso’s parents Both died of cancer when she was a teenager, inspiring her to become an oncologist and focus on developing new treatments for people with cancer. Patricia LoRusso, DO, deals with...
“It worked better than our wildest dreams,” Dr. Diaz said of a therapeutic approach that uses a tumor biomarker to identify patients likely to respond to immunotherapy. A cancer diagnosis comes with a multitude...
A career development grant from the AACR initiated the development of a model to help understand one of the deadliest and most difficult-to-treat types of cancer.
An early collaboration between AACR Fellows Joseph F. Fraumeni, MD, and Frederick P. Li, MD, defined one of the first cancer predisposition syndromes linked to the most commonly mutated gene across all cancer types. ...
Brain cancer survivor Lanette Veres started the Gray Matters Foundation, a nonprofit that provides encouragement to brain tumor patients through gift packages and cards. Read Lanette's story and the stories of other cancer survivors.
Learn More
Learn about physician-scientists and cancer researchers like Fellow of the AACR Academy Lewis C. Cantley, PhD, who are driving progress against cancer.
Learn More